| Year |
Citation |
Score |
| 2024 |
Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, O'Connor C, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowski KA, Wang L, Dehm SM, Nevalainen MT. Stat5 induces androgen receptor () gene transcription in prostate cancer and offers a druggable pathway to target AR signaling. Science Advances. 10: eadi2742. PMID 38416822 DOI: 10.1126/sciadv.adi2742 |
0.508 |
|
| 2023 |
Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, ... ... Dehm SM, et al. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. European Urology Oncology. PMID 38072760 DOI: 10.1016/j.euo.2023.11.014 |
0.373 |
|
| 2023 |
Rawat C, Ben-Salem S, Singh N, Chauhan G, Rabljenovic A, Vaghela V, Venkadakrishnan VB, Macdonald JD, Dahiya UR, Ghanem Y, Bachour S, Su Y, DePriest AD, Lee S, Muldong M, ... ... Dehm SM, et al. Prostate cancer progression relies on the mitotic kinase citron kinase. Cancer Research. PMID 37801613 DOI: 10.1158/0008-5472.CAN-23-0883 |
0.5 |
|
| 2023 |
Zivanovic A, Miller JT, Munro SA, Knutson TP, Li Y, Passow CN, Simonaitis P, Lynch M, Oseth L, Zhao SG, Feng FY, Wikström P, Corey E, Morrissey C, Henzler C, ... ... Dehm SM, et al. Co-evolution of gene copy number and structural complexity in endocrine therapy resistant prostate cancer. Nar Cancer. 5: zcad045. PMID 37636316 DOI: 10.1093/narcan/zcad045 |
0.493 |
|
| 2023 |
Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300433. PMID 37429011 DOI: 10.1200/JCO.23.00433 |
0.608 |
|
| 2023 |
Pitzen SP, Dehm SM. Basal epithelial cells in prostate development, tumorigenesis, and cancer progression. Cell Cycle (Georgetown, Tex.). 1-16. PMID 37098827 DOI: 10.1080/15384101.2023.2206502 |
0.546 |
|
| 2023 |
Zhang W, Lee AM, Jena S, Huang Y, Ho Y, Tietz KT, Miller CR, Su MC, Mentzer J, Ling AL, Li Y, Dehm SM, Huang RS. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. Proceedings of the National Academy of Sciences of the United States of America. 120: e2218522120. PMID 37068243 DOI: 10.1073/pnas.2218522120 |
0.351 |
|
| 2023 |
Bergom HE, Shabaneh A, Day A, Ali A, Boytim E, Tape S, Lozada JR, Shi X, Kerkvliet CP, McSweeney S, Pitzen SP, Ludwig M, Antonarakis ES, Drake JM, Dehm SM, et al. ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems. Communications Biology. 6: 417. PMID 37059746 DOI: 10.1038/s42003-023-04795-1 |
0.44 |
|
| 2023 |
Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L, Wang L, Yang R, Ren Y, Engle JW, Huang P, ... ... Dehm SM, et al. Expression and therapeutic targeting of Trop-2 in treatment resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36939530 DOI: 10.1158/1078-0432.CCR-22-1305 |
0.557 |
|
| 2022 |
Sicotte H, Kalari KR, Qin S, Dehm SM, Bhargava V, Gormley M, Tan W, Sinnwell JP, Hillman DW, Li Y, Vedell PT, Carlson RE, Bryce AH, Jimenez RE, Weinshilboum RM, et al. Molecular profile changes in castrate resistant prostate cancer patients pre and post-abiraterone/prednisone treatment. Molecular Cancer Research : McR. PMID 36135372 DOI: 10.1158/1541-7786.MCR-22-0099 |
0.452 |
|
| 2021 |
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, ... ... Dehm SM, et al. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications. 12: 6377. PMID 34737261 DOI: 10.1038/s41467-021-26612-1 |
0.577 |
|
| 2021 |
Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette PS, Jacobsohn KM, Tsai S, Iczkowski KA, Wang L, Hall WA, Dehm SM, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? Cancers. 13. PMID 34680353 DOI: 10.3390/cancers13205204 |
0.46 |
|
| 2021 |
Daniel M, Knutson TP, Sperger JM, Li Y, Singh A, Stahlfeld CN, Passow C, Auch B, Lang JM, Dehm SM. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer. Endocrine-Related Cancer. PMID 34280123 DOI: 10.1530/ERC-21-0157 |
0.41 |
|
| 2021 |
Guan J, Guo H, Tang T, Wang Y, Wei Y, Seth P, Li Y, Dehm SM, Ruoslahti E, Pang HB. iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis. Advanced Functional Materials. 31. PMID 34211360 DOI: 10.1002/adfm.202100478 |
0.456 |
|
| 2021 |
Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, ... ... Dehm SM, et al. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100169. PMID 34197212 DOI: 10.1200/JCO.21.00169 |
0.618 |
|
| 2021 |
Wang TY, Liu Q, Ren Y, Alam SK, Wang L, Zhu Z, Hoeppner LH, Dehm SM, Cao Q, Yang R. A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes. Molecular Cell. PMID 33861991 DOI: 10.1016/j.molcel.2021.03.028 |
0.308 |
|
| 2021 |
Ma T, Bai S, Qi Y, Zhan Y, Ungerleider N, Zhang DY, Neklesa T, Corey E, Dehm SM, Zhang K, Flemington EK, Dong Y. Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Cancer Letters. PMID 33556543 DOI: 10.1016/j.canlet.2020.12.037 |
0.512 |
|
| 2020 |
Hofmann MR, Hussain M, Dehm SM, Beltran H, Wyatt AW, Halabi S, Sweeney C, Scher HI, Ryan CJ, Feng FY, Attard G, Klein E, Miyahira A, Soule H, Sharifi N. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. PMID 33373705 DOI: 10.1016/j.urology.2020.12.021 |
0.495 |
|
| 2020 |
Eteleeb AM, Quigley DA, Zhao SG, Pham D, Yang R, Dehm SM, Luo J, Feng FY, Dang HX, Maher CA. SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. Scientific Reports. 10: 15890. PMID 32985524 DOI: 10.1038/s41598-020-71168-7 |
0.314 |
|
| 2020 |
Watson AP, Shabaneh A, Wang J, Dehm SM, Rao A, Ryan CJ. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. American Journal of Clinical and Experimental Urology. 8: 106-115. PMID 32929406 |
0.54 |
|
| 2020 |
Dehm SM, Huang H. Androgen receptor: Functional roles and facets of regulation in urology. Asian Journal of Urology. 7: 189-190. PMID 32742922 DOI: 10.1016/J.Ajur.2020.05.002 |
0.403 |
|
| 2020 |
Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, ... ... Dehm SM, et al. The DNA methylation landscape of advanced prostate cancer. Nature Genetics. PMID 32661416 DOI: 10.1038/S41588-020-0648-8 |
0.522 |
|
| 2020 |
Tietz KT, Dehm SM. Androgen receptor variants: RNA-based mechanisms and therapeutic targets. Human Molecular Genetics. PMID 32412639 DOI: 10.1093/Hmg/Ddaa089 |
0.69 |
|
| 2020 |
Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, ... ... Dehm SM, et al. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31932493 DOI: 10.1158/1078-0432.Ccr-19-3023 |
0.674 |
|
| 2020 |
Lang JM, Kyriakopoulos C, Slovin SF, Eickhoff JC, Dehm S, Tagawa ST. Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps251 |
0.559 |
|
| 2020 |
Sethakorn N, Kosoff D, Heninger E, Soto JM, Yu J, Das R, Jarrard D, Galipeau J, Hematti P, Dehm S, Beebe DJ, Lang JM. Abstract B24: A multicellular, microfluidic model of the human bone marrow niche in metastatic cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-B24 |
0.393 |
|
| 2019 |
Chaturvedi AP, Dehm SM. Androgen Receptor Dependence. Advances in Experimental Medicine and Biology. 1210: 333-350. PMID 31900916 DOI: 10.1007/978-3-030-32656-2_15 |
0.656 |
|
| 2019 |
Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S, Coleman I, Nelson PS, Dehm SM, LeBeau AM. Exploitation of CD133 for the targeted imaging of lethal prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31732520 DOI: 10.1158/1078-0432.Ccr-19-1659 |
0.531 |
|
| 2019 |
Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman I, Nelson PS, Dehm SM, LeBeau AM. PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer. Cancer Research. PMID 31530569 DOI: 10.1158/0008-5472.Can-19-2181 |
0.616 |
|
| 2019 |
Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer. Oncotarget. 10: 4920. PMID 31448058 DOI: 10.18632/oncotarget.27143 |
0.41 |
|
| 2019 |
Trembley JH, Kren BT, Abedin MJ, Shaughnessy DP, Li Y, Dehm SM, Ahmed K. CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression. Pharmaceuticals (Basel, Switzerland). 12. PMID 31197122 DOI: 10.3390/Ph12020089 |
0.657 |
|
| 2019 |
Kounatidou E, Nakjang S, McCracken SRC, Dehm SM, Robson CN, Jones D, Gaughan L. A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities. Nucleic Acids Research. PMID 31006810 DOI: 10.1093/Nar/Gkz286 |
0.623 |
|
| 2019 |
Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, ... Dehm SM, et al. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene. PMID 30742064 DOI: 10.1038/S41388-019-0732-7 |
0.549 |
|
| 2019 |
Giridhar K, Sosa C, Sicotte H, Wang L, Wang L, Sinnwell JP, Tan W, Costello BA, Quevedo F, Pitot HC, Bryce AH, Jimenez RE, Weinshilboum RM, Dehm S, Kalari KR, et al. Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P). Journal of Clinical Oncology. 37: e16559-e16559. DOI: 10.1200/Jco.2019.37.15_Suppl.E16559 |
0.505 |
|
| 2018 |
Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase promoter for the molecular imaging of prostate cancer. Oncotarget. 9: 36693-36704. PMID 30613352 DOI: 10.18632/Oncotarget.26401 |
0.614 |
|
| 2018 |
Dehm SM, Montgomery B, Plymate SR. AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30591516 DOI: 10.1158/1078-0432.Ccr-18-3727 |
0.442 |
|
| 2018 |
Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, ... ... Dehm SM, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30578319 DOI: 10.1073/Pnas.1808834116 |
0.622 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Dehm SM, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 175: 889. PMID 30340047 DOI: 10.1016/J.Cell.2018.10.019 |
0.549 |
|
| 2018 |
Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, ... ... Dehm SM, et al. A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene. PMID 30237440 DOI: 10.1038/S41388-018-0501-Z |
0.628 |
|
| 2018 |
Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, ... ... Dehm SM, et al. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology. PMID 30049486 DOI: 10.1016/J.Eururo.2018.06.020 |
0.647 |
|
| 2018 |
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, ... ... Dehm SM, et al. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. PMID 30033370 DOI: 10.1016/J.Cell.2018.06.039 |
0.591 |
|
| 2018 |
Li D, Tian G, Wang J, Zhao LY, Co O, Underill ZC, Mymryk JS, Claessens F, Dehm SM, Daaka Y, Liao D. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival. The Prostate. PMID 30009471 DOI: 10.1002/Pros.23689 |
0.638 |
|
| 2018 |
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, ... ... Dehm SM, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. PMID 29909985 DOI: 10.1016/J.Cell.2018.05.036 |
0.607 |
|
| 2018 |
Kohli M, Li J, Du M, Hillman DW, Dehm SM, Tan W, Carlson R, Campion MB, Wang L, Wang L, Zhang H, Zhang P, Kilari D, Huang CC, Wang L. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. Prostate Cancer and Prostatic Diseases. PMID 29858592 DOI: 10.1038/S41391-018-0043-Z |
0.567 |
|
| 2018 |
Kohli M, Dehm S, Bhargava V, Gormley M, Sinnwell JP, Tan W, Hillman DW, Li Y, Jimenez RE, Weinshilboum RM, Kalari KR, Wang L, Sicotte H. A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone acetate/prednisone. Journal of Clinical Oncology. 36: 5038-5038. DOI: 10.1200/Jco.2018.36.15_Suppl.5038 |
0.564 |
|
| 2018 |
Etten JLV, Nyquist M, Li Y, LaRue R, Ho Y, Yang R, Voytas DF, Henzler C, Dehm SM. Abstract 974: Alternative polyadenylation of androgen receptor variants in castration-resistant prostate cancer Cancer Research. 78: 974-974. DOI: 10.1158/1538-7445.Am2018-974 |
0.697 |
|
| 2018 |
Venkadarkrishnan VB, DePriest A, Su Y, Mudduluru G, Ben-Salem S, Kumari S, Hu Q, Cortes E, Dehm S, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers H. Abstract 3745: Inhibition of Protein Kinase N1 prevents control of AR over SRF action in advanced prostate cancer Endocrinology. DOI: 10.1158/1538-7445.Am2018-3745 |
0.553 |
|
| 2018 |
Daniel ML, Hickey TE, Carroll JS, Tilley WD, Selth LA, Dehm SM. Abstract 3741: Deciphering the regulome of androgen receptor variants in prostate cancer Cancer Research. 78: 3741-3741. DOI: 10.1158/1538-7445.Am2018-3741 |
0.699 |
|
| 2018 |
Ho Y, Etten JLV, Henzler C, Li Y, Yang R, Tseng E, Hon T, Clark T, Dehm SM. Abstract 1813: The role of androgen receptor variant AR-V9 in prostate cancer Endocrinology. DOI: 10.1158/1538-7445.Am2018-1813 |
0.637 |
|
| 2017 |
Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, ... ... Dehm SM, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology. PMID 29258679 DOI: 10.1016/J.Eururo.2017.11.038 |
0.66 |
|
| 2017 |
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, et al. A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone Acetate-Prednisone. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29069303 DOI: 10.1093/Annonc/Mdx689 |
0.579 |
|
| 2017 |
Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, Ondigi O, Voytas DF, Henzler C, Dehm SM. Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. Cancer Research. PMID 28928128 DOI: 10.1158/0008-5472.Can-17-0320 |
0.678 |
|
| 2017 |
Van Etten JL, Nyquist M, Li Y, Yang R, Ho Y, Johnson RM, Ondigi O, Voytas DF, Henzler C, Dehm SM. Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer. Cancer Research. PMID 28811331 DOI: 10.1158/0008-5472.CAN-17-0320 |
0.62 |
|
| 2017 |
Dalal K, Che M, Que NS, Sharma A, Yang R, Lallous N, Borgmann H, Ozistanbullu D, Tse R, Ban F, Li H, Tam KJ, Roshan-Moniri M, Leblanc E, Gleave ME, ... ... Dehm SM, et al. Bypassing drug-resistance mechanisms of prostate cancer with small-molecules that target androgen receptor chromatin interactions. Molecular Cancer Therapeutics. PMID 28775145 DOI: 10.1158/1535-7163.Mct-17-0259 |
0.619 |
|
| 2017 |
Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, ... ... Dehm SM, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Research. PMID 28754673 DOI: 10.1158/0008-5472.Can-17-0164 |
0.509 |
|
| 2017 |
Kohli M, Ho Y, Hillman DW, Van Etten JL, Henzler C, Yang R, Sperger JM, Li Y, Tseng E, Hon T, Clark T, Tan W, Carlson RE, Wang L, Sicotte H, ... ... Dehm SM, et al. Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28473535 DOI: 10.1158/1078-0432.Ccr-17-0017 |
0.626 |
|
| 2017 |
Paltoglou S, Das R, Townley SL, Hickey T, Tarulli G, Coutinho I, Fernandes RC, Hanson A, Denis I, Carroll J, Dehm SM, Raj GV, Plymate S, Tilley WD, Selth LA. Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer. Cancer Research. PMID 28473532 DOI: 10.1158/0008-5472.Can-16-1616 |
0.685 |
|
| 2017 |
Ho Y, Dehm SM. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. Endocrinology. PMID 28368512 DOI: 10.1210/En.2017-00109 |
0.642 |
|
| 2017 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 292: 4359. PMID 28283588 DOI: 10.1074/Jbc.A117.553818 |
0.578 |
|
| 2017 |
Isharwal S, Modi S, Arora N, Uhlrich C, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, Saluja A, Banerjee S, Konety B. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants. The Prostate. PMID 28144973 DOI: 10.1002/Pros.23298 |
0.626 |
|
| 2017 |
Kohli M, Wang L, Dehm S, Hillman DW, Sicotte H, Gormley M, Bhargava V, Ricci DS, Li W, Tan W, Costello BA, Pitot HC, Dronca RS, Ho TH, Bryce AH, et al. Association of Wnt pathway activation with prechemotherapy abiraterone acetate resistance in metastatic castration-resistant prostate cancer (mCRPC) by genome-wide analysis of metastases. Journal of Clinical Oncology. 35: 175-175. DOI: 10.1200/Jco.2017.35.6_Suppl.175 |
0.432 |
|
| 2017 |
Giridhar K, Sosa C, Hillman DW, Sanhueza CT, Wang L, Cheville JC, Dehm S, Kohli M. Whole blood androgen receptor (AR) variant (ARV12, ARV14) expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 35: 5058-5058. DOI: 10.1200/Jco.2017.35.15_Suppl.5058 |
0.574 |
|
| 2017 |
Kohli M, Wang L, Dehm S, Hillman DW, Sicotte H, Gormley M, Bhargava V, Li W, Tan W, Pitot HC, Ho TH, Costello BA, Bryce AH, Zhenqing Y, Vedell PT, et al. Genome-wide analysis of metastases to reveal association of pathway activation with abiraterone acetate/prednisone (AA/P) primary resistance and cell cycle proliferation pathway activation with response duration in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 35: 5053-5053. DOI: 10.1200/Jco.2017.35.15_Suppl.5053 |
0.485 |
|
| 2017 |
Ku KP, Lang JM, Sperger J, Dehm S, Kohli M, Wang L, Wang L, Tagawa ST, Scher HI. Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy. Journal of Clinical Oncology. 35: 5045-5045. DOI: 10.1200/Jco.2017.35.15_Suppl.5045 |
0.538 |
|
| 2017 |
Kohli M, Ho Y, Hillman DW, Etten JLV, Henzler C, Yang R, Li Y, Tseng E, Hon T, Clark TA, Wang L, Silverstein K, Wang L, Dehm SM. Abstract 425: SMRT® Sequencing of full-length androgen receptor isoforms in prostate cancer reveals previously hidden drug resistant variants Cancer Research. 77: 425-425. DOI: 10.1158/1538-7445.Am2017-425 |
0.593 |
|
| 2016 |
Henzler C, Li Y, Yang R, McBride T, Ho Y, Sprenger C, Liu G, Coleman I, Lakely B, Li R, Ma S, Landman SR, Kumar V, Hwang TH, Raj GV, ... ... Dehm SM, et al. Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nature Communications. 7: 13668. PMID 27897170 DOI: 10.1038/Ncomms13668 |
0.662 |
|
| 2016 |
Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH. CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. Oncotarget. PMID 27557516 DOI: 10.18632/Oncotarget.11442 |
0.458 |
|
| 2016 |
Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn S, Heninger E, Thiede S, Tokar J, Gibbs BK, Guckenberger DJ, Carmichael L, Dehm SM, Stephens PJ, Beebe DJ, et al. Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27401243 DOI: 10.1158/1078-0432.Ccr-16-1021 |
0.384 |
|
| 2016 |
Li Y, Dehm SM. Methods for Identifying and Quantifying mRNA Expression of Androgen Receptor Splicing Variants in Prostate Cancer. Methods in Molecular Biology (Clifton, N.J.). 1443: 165-77. PMID 27246340 DOI: 10.1007/978-1-4939-3724-0_11 |
0.665 |
|
| 2016 |
Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer and Prostatic Diseases. PMID 27184811 DOI: 10.1038/Pcan.2016.17 |
0.679 |
|
| 2016 |
Daniel M, Dehm SM. Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology. PMID 27133384 DOI: 10.1016/J.Jsbmb.2016.04.016 |
0.665 |
|
| 2016 |
Van Etten JL, Dehm SM. Clonal origin and spread of metastatic prostate cancer. Endocrine-Related Cancer. 23: R207-17. PMID 27000662 DOI: 10.1530/Erc-16-0049 |
0.605 |
|
| 2016 |
Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, ... ... Dehm SM, et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute. 108. PMID 26657335 DOI: 10.1093/Jnci/Djv371 |
0.638 |
|
| 2016 |
Kohli M, Hillman DW, Carlson R, Wang L, Li Y, Tan W, Ho TH, Sicotte H, Wang L, Costello BA, Pitot HC, Quevedo F, Dronca RS, Moynihan TJ, Atwell TD, ... ... Dehm S, et al. Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P). Journal of Clinical Oncology. 34: 237-237. DOI: 10.1200/Jco.2016.34.2_Suppl.237 |
0.45 |
|
| 2016 |
Kohli M, Hillman DW, Wang L, Li Y, Sicotte H, Carlson R, Tan W, Wu K, Eiken PW, Jimenez RE, Cernigliaro J, Quevedo F, Costello BA, Pitot HC, Moynihan TJ, ... ... Dehm S, et al. Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P). Journal of Clinical Oncology. 34: 5036-5036. DOI: 10.1200/Jco.2016.34.15_Suppl.5036 |
0.566 |
|
| 2016 |
Asim M, Massie C, Warren A, Luko K, Chohan B, Menon S, Baridi A, Orafidiya F, Zhao W, Escriu C, Mohammed H, D’Santos C, Yang X, Taylor C, Qureshi A, ... ... Dehm S, et al. Abstract LB-003: Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-003 |
0.647 |
|
| 2015 |
Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, et al. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. Plos One. 10: e0145176. PMID 26695660 DOI: 10.1371/Journal.Pone.0145176 |
0.501 |
|
| 2015 |
Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, et al. Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget. PMID 26554309 DOI: 10.18632/Oncotarget.6296 |
0.533 |
|
| 2015 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 290: 25850. PMID 26500294 DOI: 10.1074/Jbc.A115.553818 |
0.578 |
|
| 2015 |
Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research. 43: 5880-97. PMID 25908785 DOI: 10.1093/Nar/Gkv262 |
0.605 |
|
| 2015 |
Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 6: 3811-24. PMID 25669987 DOI: 10.18632/Oncotarget.2924 |
0.621 |
|
| 2015 |
Kohli M, Wang L, Sicotte H, Qin R, Carlson R, Eckel-Passow J, Tan W, Wu K, Dehm S, Eiken PW, Jimenez RE, Cernigliaro J, Quevedo F, Costello BA, Pitot HC, et al. Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 174-174. DOI: 10.1200/Jco.2015.33.7_Suppl.174 |
0.513 |
|
| 2015 |
Kohli M, Qin R, Wang L, Sicotte H, Carlson R, Tan W, Jimenez RE, Wang L, Eckel-Passow J, Costello BA, Pitot HC, Quevedo F, Dronca RS, Wu K, Moynihan TJ, ... ... Dehm S, et al. A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 5056-5056. DOI: 10.1200/Jco.2015.33.15_Suppl.5056 |
0.449 |
|
| 2015 |
Heine E, Merry DE, Dehm S, Knudsen KE, Montie HL. Abstract 87: Targeting androgen receptor acetylation as a treatment for castrate-resistant prostate cancer Cancer Research. 75: 87-87. DOI: 10.1158/1538-7445.Am2015-87 |
0.682 |
|
| 2015 |
Liu G, Li A, Sun S, Sprenger C, Corey E, Morrisey C, Dehm S, Plymate S. Abstract 5159: Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody Cancer Research. 75: 5159-5159. DOI: 10.1158/1538-7445.Am2015-5159 |
0.594 |
|
| 2015 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Guns ET, Cherkasov A, Rennie PS. Abstract 1778: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer Cancer Research. 75: 1778-1778. DOI: 10.1158/1538-7445.Am2015-1778 |
0.62 |
|
| 2015 |
Dehm SM. Abstract CN06-02: Regulation of AR variants by BET bromodomains in prostate cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Cn06-02 |
0.692 |
|
| 2014 |
Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. The Journal of Biological Chemistry. 289: 26417-29. PMID 25086042 DOI: 10.1074/Jbc.M114.553818 |
0.633 |
|
| 2014 |
Chan SC, Dehm SM. Constitutive activity of the androgen receptor. Advances in Pharmacology (San Diego, Calif.). 70: 327-66. PMID 24931201 DOI: 10.1016/B978-0-12-417197-8.00011-0 |
0.655 |
|
| 2014 |
Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocrine-Related Cancer. 21: T87-T103. PMID 24859991 DOI: 10.1530/Erc-13-0470 |
0.623 |
|
| 2013 |
Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 17492-7. PMID 24101480 DOI: 10.1073/Pnas.1308587110 |
0.663 |
|
| 2013 |
Dehm SM. Test-firing ammunition for spliceosome inhibition in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6064-6. PMID 24097858 DOI: 10.1158/1078-0432.Ccr-13-2461 |
0.385 |
|
| 2013 |
Dehm SM. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Research. 73: 5309-14. PMID 23970479 DOI: 10.1158/0008-5472.Can-13-0444 |
0.474 |
|
| 2013 |
Brand LJ, Dehm SM. Androgen receptor gene rearrangements: new perspectives on prostate cancer progression. Current Drug Targets. 14: 441-9. PMID 23410127 DOI: 10.2174/1389450111314040005 |
0.679 |
|
| 2013 |
Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. The Prostate. 73: 1017-27. PMID 23389878 DOI: 10.1002/Pros.22649 |
0.642 |
|
| 2013 |
Nyquist MD, Dehm SM. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression. Hormones & Cancer. 4: 61-9. PMID 23307762 DOI: 10.1007/S12672-013-0131-4 |
0.634 |
|
| 2013 |
Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research. 73: 483-9. PMID 23117885 DOI: 10.1158/0008-5472.Can-12-3630 |
0.63 |
|
| 2013 |
Nyquist MD, Li Y, Dehm SM. Abstract LB-136: Creation of androgen independent prostate cancer cell lines using targeting nucleases. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-136 |
0.651 |
|
| 2013 |
Brand LJ, Dehm SM. Abstract 1325: Chlorinated bisphenol A diglycidyl ether (EPI-001) mediates degradation of the androgen receptor in prostate cancer cells. Cancer Research. 73: 1325-1325. DOI: 10.1158/1538-7445.Am2013-1325 |
0.681 |
|
| 2012 |
Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Advances in Urology. 2012: 781459. PMID 22956944 DOI: 10.1155/2012/781459 |
0.607 |
|
| 2012 |
Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. The Journal of Biological Chemistry. 287: 19736-49. PMID 22532567 DOI: 10.1074/Jbc.M112.352930 |
0.61 |
|
| 2012 |
Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 31: 4759-67. PMID 22266865 DOI: 10.1038/Onc.2011.637 |
0.625 |
|
| 2012 |
Dehm SM. Abstract IA18: Altered AR gene architecture and splicing in castration-resistant prostate cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Prca2012-Ia18 |
0.655 |
|
| 2011 |
Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocrine-Related Cancer. 18: R183-96. PMID 21778211 DOI: 10.1530/Erc-11-0141 |
0.647 |
|
| 2011 |
Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research. 71: 2108-17. PMID 21248069 DOI: 10.1158/0008-5472.Can-10-1998 |
0.643 |
|
| 2011 |
Li Y, Alsagabi M, Tewfik A, Dehm SM. Abstract 4556: AR intragenic rearrangement and altered androgen receptor mRNA splicing in castration-resistant prostate cancer Cancer Research. 71: 4556-4556. DOI: 10.1158/1538-7445.Am2011-4556 |
0.669 |
|
| 2009 |
Shin S, Kim TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G, Janknecht R. Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Research. 69: 8102-10. PMID 19789348 DOI: 10.1158/0008-5472.Can-09-0941 |
0.634 |
|
| 2008 |
Raclaw KA, Heemers HV, Kidd EM, Dehm SM, Tindall DJ. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. The Prostate. 68: 1696-706. PMID 18726983 DOI: 10.1002/Pros.20844 |
0.609 |
|
| 2008 |
Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research. 68: 5469-77. PMID 18593950 DOI: 10.1158/0008-5472.Can-08-0594 |
0.676 |
|
| 2007 |
Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Research. 67: 10592-9. PMID 17975004 DOI: 10.1158/0008-5472.Can-07-1917 |
0.677 |
|
| 2007 |
Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Research. 67: 10067-77. PMID 17942941 DOI: 10.1158/0008-5472.Can-07-1267 |
0.656 |
|
| 2007 |
Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 21: 2855-63. PMID 17636035 DOI: 10.1210/Me.2007-0223 |
0.67 |
|
| 2006 |
Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. The Journal of Biological Chemistry. 281: 27882-93. PMID 16870607 DOI: 10.1074/Jbc.M605002200 |
0.619 |
|
| 2006 |
Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. Journal of Cellular Biochemistry. 99: 333-44. PMID 16518832 DOI: 10.1002/Jcb.20794 |
0.643 |
|
| 2005 |
Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Research. 65: 5965-73. PMID 15994976 DOI: 10.1158/0008-5472.Can-04-2837 |
0.63 |
|
| 2005 |
Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Review of Anticancer Therapy. 5: 63-74. PMID 15757439 DOI: 10.1586/14737140.5.1.63 |
0.651 |
|
| 2004 |
Dehm SM, Bonham K. Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cells. Gene. 337: 141-50. PMID 15276210 DOI: 10.1016/J.Gene.2004.04.021 |
0.377 |
|
| 2004 |
Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 82: 263-74. PMID 15060621 DOI: 10.1139/O03-077 |
0.406 |
|
| 2004 |
Dehm SM, Hilton TL, Wang EH, Bonham K. SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Molecular and Cellular Biology. 24: 2296-307. PMID 14993269 DOI: 10.1128/Mcb.24.6.2296-2307.2004 |
0.326 |
|
| 2002 |
Kostyniuk CL, Dehm SM, Batten D, Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene. 21: 6340-7. PMID 12214274 DOI: 10.1038/Sj.Onc.1205787 |
0.397 |
|
| 2001 |
Dehm S, Senger MA, Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. Febs Letters. 487: 367-71. PMID 11163360 DOI: 10.1016/S0014-5793(00)02354-1 |
0.353 |
|
| 2000 |
Bonham K, Ritchie SA, Dehm SM, Snyder K, Boyd FM. An alternative, human SRC promoter and its regulation by hepatic nuclear factor-1alpha. The Journal of Biological Chemistry. 275: 37604-11. PMID 10978326 DOI: 10.1074/Jbc.M004882200 |
0.325 |
|
| 2000 |
Rajala RV, Dehm S, Bi X, Bonham K, Sharma RK. Expression of N-myristoyltransferase inhibitor protein and its relationship to c-Src levels in human colon cancer cell lines. Biochemical and Biophysical Research Communications. 273: 1116-20. PMID 10891381 DOI: 10.1006/Bbrc.2000.3066 |
0.361 |
|
| Show low-probability matches. |